American Well (NYSE:AMWL) Insider Phyllis Gotlib Sells 4,959 Shares

American Well Corporation (NYSE:AMWL) insider Phyllis Gotlib sold 4,959 shares of American Well stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $6.11, for a total transaction of $30,299.49. Following the completion of the sale, the insider owned 127,151 shares in the company, valued at approximately $776,892.61. This trade represents a 3.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Phyllis Gotlib also recently made the following trade(s):

• On Tuesday, September 2nd, Phyllis Gotlib sold 4,781 shares of American Well stock. The shares were sold at an average price of $6.78, for a total transaction of $32,415.18.

American Well Trading Up 3.6%

AMWL stock opened at $6.34 on Monday. American Well Corporation has a 12-month low of $5.98 and a 12-month high of $12.95. The business’s 50-day moving average is $6.92 and its 200 day moving average is $7.27. The stock has a market cap of $102.39 million, a price-to-earnings ratio of -0.79 and a beta of 1.26.

American Well (NYSE:AMWL) last announced its earnings results on Tuesday, August 5th. The company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.84) by $0.60. The business had revenue of $70.90 million during the quarter, compared to analysts’ expectations of $63.87 million. American Well had a negative return on equity of 41.99% and a negative net margin of 46.15%. American Well has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts forecast that American Well Corporation will post -9.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on AMWL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of American Well in a research note on Saturday, September 27th. Wells Fargo & Company lowered their price target on shares of American Well from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $9.17.

Institutional Investors Weigh In On American Well

Hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new stake in American Well during the second quarter worth $39,000. Sapient Capital LLC purchased a new position in American Well during the first quarter worth about $79,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in American Well during the second quarter worth about $89,000. Engineers Gate Manager LP acquired a new stake in shares of American Well during the second quarter valued at about $101,000. Finally, JPMorgan Chase & Co. raised its stake in shares of American Well by 16.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock valued at $131,000 after acquiring an additional 2,081 shares during the period. 56.05% of the stock is currently owned by institutional investors and hedge funds.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.